Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device (ADMIRE-ICD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02656329
Recruitment Status : Terminated (Sponsor discretion (low recruitment rate))
First Posted : January 14, 2016
Results First Posted : May 22, 2019
Last Update Posted : May 22, 2019
Sponsor:
Collaborators:
Advanced Clinical, LLC
TFS
H2O Clinical LLC
AG Mednet Inc.
ICON CEAC
ICON Clinical
ABX CRO
TransPerfect
Information provided by (Responsible Party):
GE Healthcare

Brief Summary:
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure participants with 25%<=left ventricular ejection fraction (LVEF)<=35%, and in particular, for identifying participants who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Iobenguane I -123 Injection Device: Implantable Cardioverter Defibrillator Drug: Thyroid blocking Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 395 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%
Actual Study Start Date : December 30, 2015
Actual Primary Completion Date : May 4, 2018
Actual Study Completion Date : May 4, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: AdreView™
Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
Drug: Iobenguane I -123 Injection
Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Other Names:
  • AdreView
  • Iobenguane I-123 Injection

Device: Implantable Cardioverter Defibrillator
In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.

Drug: Thyroid blocking
Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
Other Names:
  • Potassium Iodide
  • Potassium Perchlorate
  • Lugol's Solution

Experimental: Standard of Care
Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
Drug: Iobenguane I -123 Injection
Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Other Names:
  • AdreView
  • Iobenguane I-123 Injection

Device: Implantable Cardioverter Defibrillator
All participants allocated to the SoC (control) group underwent ICD implantation.




Primary Outcome Measures :
  1. All-cause Mortality [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    All-cause mortality included all reported deaths of participants during the study due to any cause. Percentage of participants who died due to any cause were reported.


Secondary Outcome Measures :
  1. Percentage of Participants With Events of Complications of Device: H/M >=1.6 in Full Analysis Set [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device' for participants with H/M >=1.6. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.

  2. Percentage of Participants With Cardiac Death [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Cardiac death composed of sudden cardiac death, death due to cardiac arrhythmia, death due to heart failure, and death due to other cardiovascular causes.

  3. Percentage of Participants With Hospitalization for Cardiovascular Cause [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Percentage of participants who were hospitalized for cardiovascular cause were reported.

  4. Percentage of Participants With All-Cause Hospitalization [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Percentage of participants with all-cause hospitalization were reported.

  5. Percentage of Participants With Events (Composite of the Occurrence of Resuscitated Life-Threatening Ventricular Tachycardia, Unstable Ventricular Tachyarrhythmias, Sudden Cardiac Death [SCD] and Resuscitated Cardiac Arrest) [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Percentage of participants with composite events i.e occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tachy-arrhythmias, SCD and resuscitated cardiac arrest were reported. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.

  6. Percentage of Participants With Syncope [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Percentage of participants with Syncope were reported. Participants who were alive at time of DBL were censored at the last known-alive date by date of DBL.

  7. Percentage of Participants With Implantable Cardioverter Defibrillator (ICD) Implantation [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Percentage of participants with ICD implantation were reported.

  8. Percentage of Participants With Events of Complications of Device [ Time Frame: From randomization until the end of the follow-up period (median 304 days) ]
    Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device'.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants >=18 years of age at the time dated informed consent was obtained.
  • Female participants must be pre-menarchal, surgically sterile (had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or, if of childbearing potential, a serum or urine pregnancy test with the results known prior to AdreView (Iobenguane I-123 Injection) administration) was negative.
  • Participants willing and able to comply with all study procedures and a signed and dated informed consent was obtained before any study-procedure was carried out.
  • Heart failure NYHA class II or III for symptoms, participants with ischemic or non-ischemic heart disease, eligible for ICD implantation as per each site's standard of practice.
  • Non-ischemic dilated cardiomyopathy or ischemic heart disease of at least 3 months duration receiving guideline-directed optimal medical therapy.
  • 25%≤LVEF≤35%, performed within 3 months before or at time of enrollment, as measured by radionuclide ventriculography, or electrocardiogram [ECG]-gated SPECT myocardial perfusion imaging [MPI], or magnetic resonance imaging [MR], computed tomography [CT], or 3D or 2D echocardiography [Simpson's or multidisc method only, M-mode echocardiography was not accepted].

In case LVEF measurement was performed within 3 months before enrollment, measurement should be performed at least 40 days after a hospitalization for HF or acute coronary syndrome (including myocardial infarction), and to be valid, method of measurement should be in accordance with the protocol and the imaging exam should be made available to the Sponsor in digital format. In case several valid LVEF measurements are available, the closest to enrollment will be used for inclusion determination.

  • Clinically stable heart failure in the medical judgment of the investigator (i.e. no significant changes in medication, no worsening of symptoms, no unscheduled visits to the doctor's office) for the past 30 days and no hospitalization for heart failure or acute coronary syndrome (including myocardial infarction) in the past 40 days.
  • Reasonable expectation of meaningful survival for at least 1 year.

Exclusion Criteria:

  • Participants with existing ICD or participant having an indication of ICD implantation for secondary prevention of sudden cardiac death.
  • Hospitalization for HF or for acute coronary syndrome in the previous 40 days.
  • Participants where a cardiac resynchronisation therapy (CRT) was planned or indicated.
  • Other indication for placement of device (sustained ventricular tachycardia, resuscitated sudden death, need for atrioventricular pacing).
  • NYHA class I or class IV symptoms at the time of study entry.
  • Participants with chronic renal insufficiency defined as serum creatinine ≥ 3 mg/dl (or ≥ 265.2 µmol/L).
  • American College of College-American Heart Association (ACC-AHA) class III or class IV (unstable) angina.
  • Known or suspected hypersensitivity/allergy to Iobenguane or to any of the excipients an Adreview (Iobenguane I-131 injection).
  • Participant who was pregnant or plans to become pregnant within 2 weeks after AdreView (Iobenguane I-123 Injection) administration.
  • Participant who had used any medication in the 2 weeks before AdreView (Iobenguane I-123 Injection) that could interfere with the test: e.g. but not limited to amitriptyline or derivatives, imipramine or derivatives, other antidepressants or drugs known or suspected to inhibit the norepinephrine transporter, antihypertensives that deplete norepinephrine stores or inhibit reuptake, sympathomimetic amines or cocaine.
  • Participants that had a medical condition that could interfere with the AdreView test (e.g. but not limited to left ventricular assist device (LVAD), or prior heart transplant).
  • Participants who participated in a clinical study involving a drug or device within 30 days prior to study entry and participants participating in any other clinical study.
  • Participants having serious non-cardiac medical condition associated with significant elevation of plasma catecholamines, including pheochromocytoma.
  • Participants with a clinical diagnosis of (or being treated for) Parkinson's disease or Multiple System Atrophy.
  • The participant had participated in a research study using ionizing radiation in the previous 12 months.
  • Participants previously randomized in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02656329


  Show 94 Study Locations
Sponsors and Collaborators
GE Healthcare
Advanced Clinical, LLC
TFS
H2O Clinical LLC
AG Mednet Inc.
ICON CEAC
ICON Clinical
ABX CRO
TransPerfect
  Study Documents (Full-Text)

Documents provided by GE Healthcare:
Study Protocol  [PDF] May 11, 2017
Statistical Analysis Plan  [PDF] June 20, 2018


Layout table for additonal information
Responsible Party: GE Healthcare
ClinicalTrials.gov Identifier: NCT02656329     History of Changes
Other Study ID Numbers: GE-122-020
2015-001464-19 ( EudraCT Number )
First Posted: January 14, 2016    Key Record Dates
Results First Posted: May 22, 2019
Last Update Posted: May 22, 2019
Last Verified: April 2019

Keywords provided by GE Healthcare:
Heart Failure (HF)
Single photon emission computer tomography scan (SPECT)
Implantable cardioverter defibrillator (ICD)
Left Ventricular ejection fraction (LVEF)
New York Health Association (NYHA)
Metaiodobenzylguanidine (mIBG)
123I-iobenguane
Heart-to-mediastinal ratio (H/M)
ADMIRE-ICD (AdreView Myocardial Imaging for Risk Evaluation - Implantable Cardioverter Defibrillator
All-cause mortality
Cardiac mortality

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
3-Iodobenzylguanidine
Lugol's solution
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals
Hemostatics
Coagulants